Executive operations and strategic development at ALX Oncology are led by Jaap Mulder, who serves as the President and Chief Executive Officer. Bringing extensive biotechnology and pharmaceutical leadership experience, the CEO oversees the advancement of its clinical pipelines, corporate partnerships, research collaborations, and capital allocation frameworks designed to bring novel cancer therapies through human clinical trials.